Annovis Bio, Inc. ANVS
1.31
(0.02)
(1.50%)
as of 25 Sep
- Market cap
- $56.8M
- P/E
- 0.0×
Follow ANVS
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(246.14%) | (220.61%) | (301.13%) | (703.68%) | |
| (157.74%) | (164.85%) | (190.43%) | (227.74%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(184.94%) | (165.39%) | (1,185.13%) | (315.88%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.27) | (1.25) | (0.95) | (1.16) | |
Free Cash Flow |
(24.98) | (25.62) | (26.53) | (43.34) | |
Piotroski F-Score |
2.00 | 3.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(87.82%) | (70.42%) | (152.97%) | (299.43%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.00 | 0.89 | 0.65 | 0.88 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.27) | (1.25) | (0.95) | (1.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates